Orphan Drug Exclusivity, Collaborations, and New Drug Submissions Boost Growth - Research Report on Raptor Pharmaceutical, Seattle Genetics, Arena Pharmaceuticals, WellCare, and Impax Laboratories Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, July 1, 2013 NEW YORK, July 1, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Seattle Genetics, Inc. (NASDAQ: SGEN), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), WellCare Health Plans, Inc. (NYSE: WCG), and Impax Laboratories Inc. (NASDAQ: IPXL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Raptor Pharmaceutical Corp. Research Report On June 25, 2013, Raptor Pharmaceutical Corp. (Raptor Pharmaceutical) announced that the Office of Orphan Product Development at the Food and Drug Administration (FDA) has granted the Company orphan drug exclusivity for PROCYSBI (cysteamine bitartrate) delayed-release capsules for the management of nephropathic cystinosis patients of the age six and above. According to the Company, nephropathic cystinosis comprises 95% of cases of cystinosis, a rare, life-threatening metabolic lysosomal storage disorder that causes toxic accumulation of cysteine in all cells, tissues, and organs in the body. If untreated, the disease is usually fatal by the end of the first decade of life. Thomas E. Daley, Chief Business Officer of Raptor Pharmaceutical, said, "The exclusivity also adds incremental protection alongside our issued patents listed in the FDA's Orange Book with expirations in 2027." The exclusivity period began on the date of FDA approval (April 30, 2013), and will last seven years, subject to certain exceptions. The Full Research Report on Raptor Pharmaceutical Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/a301_RPTP] -- Seattle Genetics,Inc. Research Report On June 25, 2013, Seattle Genetics, Inc. (Seattle Genetics) announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). With this relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to use Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets. Additionally, Seattle Genetics stated that it is eligible to receive up to $500 million in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration. Natasha Hernday, Vice President, Corporate Development, at Seattle Genetics, said, "Across internal and collaborator programs, there are more than 15 ADCs in clinical development using our technology, and we have the potential to receive more than $3.5 billion in future milestones plus royalties from these strategic alliances." The Full Research Report on Seattle Genetics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/f796_SGEN] -- Arena Pharmaceuticals,Inc. Research Report On June 26, 2013, Arena Pharmaceuticals, Inc. (Arena) announced that Eisai Limited, a subsidiary of Eisai Inc. (Eisai), has submitted a New Drug Submission (NDS) for BELVIQ (lorcaserin HCl) with Health Canada. According to Arena, BELVIQ is being evaluated in Canada as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adult obese patients (initial body mass index, or BMI, ≥ 30 kg/m2), or overweight patients (initial BMI ≥ 27 kg/m2) in the presence of at least one additional cardiovascular risk factor (e.g., hypertension, dyslipidemia, type 2 diabetes, or sleep apnea). Arena manufactures BELVIQ in Switzerland, and sells the finished product to Eisai for distribution. In connection with the NDS, Arena reported that it will receive a milestone payment of $500,000 from Eisai. The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/6991_ARNA] -- WellCare Health Plans,Inc. Research Report On June 26, 2013, WellCare Health Plans, Inc. (WellCare) announced that it is supporting healthy eating habits among low-income youth and their families by sponsoring 22 community gardens across Georgia. According to WellCare, this statewide initiative involves planting and growing gardens in local communities in order to provide easy access to nutritionally rich food that may otherwise be unavailable to low-income families, while encouraging a sense of community ownership. Jesse Thomas, WellCare's South Division President, said, "Across Georgia, WellCare is working to engage with our communities on healthy eating and healthy living." WellCare informed that this initiative was launched in May 2013 and will continue throughout the summer of 2013. The Full Research Report on WellCare Health Plans, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/be42_WCG] -- Impax Laboratories Inc. Research Report On June 25, 2013, Impax Laboratories Inc. (Impax) announced that Dr. Larry Hsu plans to retire as President and CEO of the Company. Dr. Hsu will remain in his current position with the Company until a new CEO is named, and will also remain a member of the Company's Board of Directors following the appointment of his successor. Bob Burr, Chairman of the Board of Directors of Impax, said, "Since becoming CEO in 2006, Larry has led Impax through an important period of substantial growth resulting in a four-fold increase in revenues, a strong balance sheet, initiating the Company's brand strategy and successfully positioning the Company for long-term future growth." He added, "The Board of Directors remains confident in and committed to the Company's strategic direction. We are focused on finding a successor CEO that will lead Impax through its future growth." The Full Research Report on Impax Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/425d_IPXL] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Orphan Drug Exclusivity, Collaborations, and New Drug Submissions Boost Growth - Research Report on Raptor Pharmaceutical,
Press spacebar to pause and continue. Press esc to stop.